Home > Insider Trading > Filing (0001179110-15-016285)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1157601	Synta Pharmaceuticals Corp	SNTA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1325712	R Keith Gollust	C/O Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington MA 02421		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2015-12-11	300,000	$0.37	1,839,169	No	4	S	Indirect	By Wyandanch Partners, L.P.
Common Stock	Disposition	2015-12-14	300,000	$0.32	1,539,169	No	4	S	Indirect	By Wyandanch Partners, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Wyandanch Partners, L.P.
No	4	S	Indirect	By Wyandanch Partners, L.P.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	401,764	Direct
Common Stock	175,000	Indirect	By Keith R. Gollust IRA

Footnotes

This transaction was executed in multiple trades at prices ranging from $0.35 to $0.3833 per share. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
This transaction was executed in multiple trades at prices ranging from $0.2901 to $0.3535 per share. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.